plaque rupture or erosion, followed by thrombus formation and arterial occlusion. Inflammation is associated with all forms of atherosclerotic plaques [3, 4] . Adipose tissue secretes several adipocytokines, including visfatin, leptin, adiponectin, omentin-1, and tumor necrosis factoralpha (TNF-α). These adipokines play an important role in the pathogeneses of insulin resistance, diabetes mellitus, dyslipidemia, inflammation, and atherosclerosis [5, 6] . TNF-α, a proinflammatory cytokine and a main mediator of inflammation, is predominately expressed in atherosclerotic lesions [7, 8] . Visfatin, a 52 kDa protein, is an adipokine originally discovered in the liver, skeletal muscle, and bone marrow as a growth factor for B lymphocyte precursors. It was first named pre-B-cell colony enhancing factor [9] [10] [11] . Visfatin, suggested to be an insulin-mimetic adipokine, is mainly produced in adipose tissue and macrophages. Visfatin displays a proinflammatory action and is localized in macrophage foam cells [12, 13] . According to 1 study, visfatin and TNF-α levels demonstrated a positive correlation with a radiographic progression of atherosclerosis in patients with rheumatoid arthritis [14] ; thus, they might be useful markers for disease progression in the early stages. Biomarkers play important roles in the diagnosis, risk assessment, and monitoring of patients with ACS. Today, troponins, creatine kinase-MB (CK-MB), and myoglobin are popular markers used in the early diagnosis and monitoring of ACS. However, the previously advocated use of myoglobin as an early marker of ACS has recently been discouraged, mainly because of its poor performance compared with precise and sensitive troponin assays [15, 16] . Investigations continue for the means to identify patients with ACS and make earlier coronary intervention possible. There are some studies in the literature investigating the serum visfatin level in metabolic syndrome and myocardial infarction (MI). However, to the best of our knowledge, there are no studies examining visfatin as a proinflammatory biomarker for monitoring ACS. The aim of the present study was to investigate visfatin as a biomarker in the early diagnosis and monitoring of ACS and to evaluate its relationship with troponin T, TNF-α, and CK-MB.
Materials and Methods

Study subjects
Sixty ACS patients (Group 1) and 30 control subjects (Group 2) were recruited into this study. Thirty healthy participants were selected from among hospital staff volunteers as a control group who were matched for age, gender, and body mass index (BMI) with the patients. This study was conducted in accordance with the Declaration of Helsinki and was approved by the medical ethics committee of Manisa Celal Bayar University Faculty of Medicine (approval number: 20478486-0.50.04.04). All of the participants in the study supplied informed consent and answered a questionnaire prepared for their health records. The ACS patient group was selected from consecutive adults admitted to the emergency department with acute chest pain. The diagnosis was established as coronary heart disease according to clinical symptoms, electrocardiogram findings, and cardiac markers, and confirmed with coronary angiography performed using a femoral access in the cardiology department of Manisa Celal Bayar Hospital. Patients presenting with dyspnea after a trauma or malignancy, and patients who declined to participate in the study were excluded. Other exclusion criteria were the presence of diabetes mellitus, chronic inflammatory disease, liver disease, muscle disease, chronic renal failure, or a previous coronary angiography.
Sample collection
Venous blood samples were collected 3 times from the patients at intervals of 0-6 hours (T0), 6-12 hours (T1), and 12-24 hours (T2) after the onset of the first symptoms. The controls provided a single venous sample. All of the blood samples were collected into serum separator tubes, centrifuged at 3000 g for 4 minutes at 4°C, and the sera samples were stored at -80°C until analysis.
Assay methods
The serum visfatin levels were assessed using the enzymelinked immunosorbent assay (ELISA) method and a Human Visfatin ELISA Kit (Alpco Diagnostics, Salem, NH, USA). The sensitivity was 30pg/mL, the intra-assay coefficient of variation (%CV) was 4.31, and the inter-assay %CV was 7.58. The TNF-α levels were also assessed using the ELISA method with a commercial kit (Biosource, Europe S. A., Nivelles, Belgium). The sensitivity was 1.7 pg/mL, the intra-assay %CV was 4.4, and the inter-assay %CV was 7.5. The serum troponin T levels were determined using the chemiluminescence method (Elecsys 2010; Hitachi, Tokyo, Japan). Serum glucose, urea, creatinine, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, CK-MB, triglyceride, cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels were assessed with an auto-analyzer (Synchron Unicel DXC 800; Beckman Coulter, Fullerton, CA, USA) and commercial kits (Beckman Coulter, Inc., Brea, CA, USA). BMI was calculated using the formula of weight (kg)/height (m) 2 . 
Statistical analysis
Results
Sixty ACS patients matched for age, gender, and BMI with 30 thirty control subjects were included in the study. The demographic data and routine biochemical parameters of the study groups are shown in Table 1 . The visfatin, TNF-α, troponin T, and CK-MB level results at T0 are displayed in Table 2 . The visfatin levels were not statistically higher in ACS patients than in the controls at T0 (4.01±6.23 vs. 1.46±1.18; p=0.128). The changes in the level of visfatin, TNF-α, troponin T, and CK-MB at T0, T1, and T2 are presented in Table 3 . The visfatin level was highest at T0; the T1 and T2 levels were statistically significantly lower than that of T0. There was no significant difference between T1 and T2 in the visfatin level. Correlations between visfatin and troponin T, TNF-α, and CK-MB at T0 are shown in Table 4 . In the T0 interval, a positive correlation was observed between visfatin and troponin T (r=+0.290; p=0.007).
In the ACS group, 63.3% (n=38) were diagnosed with STEMI, 21.7% (n=13) were diagnosed with UAP, and 15.0% (n=9) with NSTEMI. There were no statistically significant differences in the visfatin level between the controls and the STEMI, NSTEMI, and UAP patients (data not shown).
Discussion
ACS is the most common cause of mortality and morbidity in the world. There are 4 pathological mechanisms in ACS: systemic inflammation with plaque rupture, plaque rupture without systemic inflammation, erosion of plaque, and plaque without thrombus [17] . An atherosclerotic plaque is composed of both intracellular and extracellular lipid-containing vascular smooth muscle cells and inflammatory cells [3] . Excessive adipose tissue surrounding the blood vessels may lead to increased perivascular fat, and thus may stimulate an inflammatory state. A chronic state of inflammation in the adipose tissue causes an increase in the secretion of proinflammatory cytokines, such as interleukin 6 (IL-6), adiponectin, and TNF-α, which might also cause endothelial dysfunction [18] . While inflammation is associated with all forms of atherosclerotic plaques, stable plaques are characterized by chronic inflammation and unstable plaques by acute inflammation. The pathogenic role of macrophages and lymphocytes in plaque destabilization is believed to be associated with the secretion of cytokines and lytic enzymes, thereby predisposing a lesion to rupture. The adipose tissuederived circulating inflammatory markers are thus important in this process. Since pro-inflammatory cytokines and chemokines are thought to be responsible for plaque rupture, anti-inflammatory therapy and immune-modulatory treatment are under investigation [4] . There are some conflicting data in the literature regarding TNF-α level in patients with coronary heart disease. Some studies have suggested that TNF-α, as the main mediator of inflammation, is present in atherosclerotic lesions and causes progression and ruptures in atherosclerotic plaques [7, 8, 19] . A study revealed that the TNF-α levels from epicardial and abdominal adipose tissue were higher in patients with myocardial infarction and UAP than in controls [20] , similar to our findings. Kręcki et al. [21] found significantly higher TNF-α levels in coronary heart disease patients than in their controls. However, in a study including ischemic coronary patients and controls, Djordjevic et al. [22] did not find a statistically significant difference between the TNF-α level of the patients and that of the controls. Torre-Amione et al. [23] reported that TNF-α concentrations were significantly greater in patients with ischemic heart disease. It has been suggested that TNF-α is an important contributor to cardiomyocyte death post MI [24] . In our study, the TNF-α level was significantly higher in the patient group than in the control group in the first 6 hours due to inflammation, which is consistent with the literature. However, the TNF-α level decreased significantly after the first 6 hours (T1). Therefore, we believe that the use of TNF-α in the monitoring of ACS patients would not be beneficial. Adipose tissue is an endocrine organ which can secrete adipocytokines like visfatin, TNF-α, adiponectin, leptin, and resistin [25] . In obese patients, macrophages in white adipose tissue were shown to be responsible for the production of visfatin more than adipocytes [26] . Visfatin is also released by the adipose tissue of the epicardium and may influence cardiac activity. A study demonstrated that visfatin levels in abdominal and epicardial adipose tissue were significantly greater in coronary artery disease patients in comparison with controls [27] . Moreover, the serum visfatin levels were positively related to the fat thickness of the epicardium. Therefore, visfatin is considered to be a serious risk factor for coronary artery disease patients [27] . Visfatin displays proinflammatory activity in human monocytes and vascular endothelial cells [28, 29] . Visfatin has been described in the literature as activating endothelial nitric oxide synthase and improving endothelial cell function via angiogenesis [30] . Essentially, visfatin was found to be a significant protective protein in endothelial cells by prohibiting endothelial cells from aging and injury [31] . Visfatin can be linked to inflammatory actions of endothelial cells [32] . Visfatin exhibits an essential role in inflammation and oxidation, with possible leads to endothelial dysfunction [33] .
However, the precise role of visfatin remains controversial. It has been shown to have a proinflammatory effect, since it induced the expression of TNF-α and interleukin 6 in leukocytes [29] , and it is called a harmful agent because of so-called proinflammatory effects in cardiovascular and metabolic disorders [20] . A meta-analysis [34] reported that in obese subjects with type 2 diabetes mellitus [35] and metabolic syndrome, elevated visfatin levels were determined to be risk factors for cardiovascular disease [36] . Higher visfatin levels are also related to high blood pressure and higher levels of C-reactive protein and low-density lipoprotein cholesterol (LDL-C) [36] . There is also a direct correlation between higher visfatin levels and cardiac enzymes. Lu et al. [37] suggested that visfatin might be a marker of increased cardiovascular risk. Contrary to those findings, potential beneficial effects of visfatin have been determined by other researchers. Smith et al. [38] reported that visfatin level had a positive correlation with the beneficial lipoproteins high-density lipoprotein cholesterol and apolipoprotein A1. In another study, Lim et al. [39] observed a reduction in infarct size with visfatin treatment in a murine model. In another study, the visfatin level was found to be upregulated in rat heart tissue with wine consumption, possibly by the cardioprotective components of hydroxytyrosol resveratrol and tyrosol, [40] implying that visfatin may be cardioprotective. Hsu et al. [41] suggested that visfatin can protect against MI via coordinating autophagy of cardiomyocytes. Alternatively, Choi et al. [42] evaluated lipocalin-2 and visfatin levels in coronary heart disease patients and they found that visfatin levels were not significantly different between the coronary artery disease patients and controls.
Visfatin is known to be an inflammatory protein associated with plaque destabilization and ACS [12, 43] . Chiu et al. [44] histochemically examined visfatin in leukocytes isolated from the blood of patients with acute STEMI and from macrophages isolated from coronary ruptured plaques. They suggested that visfatin might play a role in atherosclerotic plaque rupture. Similar to their findings, in our study, visfatin levels in patients with ACS were elevated in the first 6 hours after the onset of symptoms, which Chiu et al. explained as an accelerated monocyte and neutrophil yield in correlation with the visfatin level. Yang et al. [45] suggested that elevated plasma visfatin levels increased the risk of MI, and that visfatin may be a promising biomarker for MI. Lu et al. [37] found that plasma visfatin levels were significantly higher in MI cases and that the elevated visfatin level were correlated with higher cardiac enzymes levels. They proposed that increased plasma visfatin may be linked to myocardial damage. However, the mechanism of visfatin in cardiovascular diseases still needs to be further elucidated. In our study, the visfatin level was not statistically significantly greater in the ACS patients than in the healthy subjects in first 6 hours. There was a positive correlation between visfatin and troponin T in the first 6 hours; however, according to our statistical data, visfatin was not superior to classic cardiac biomarkers such as troponin for the early diagnosis and monitoring of ACS. We think that the role of visfatin in the early period of ACS may be better understood by examining the changes in visfatin level in first 6 hours of ACS. Due to both plaque destabilization and cardioprotective effects, visfatin may be a dual effective adipokine, such as adiponectin. Further studies are needed for the complete clarification of the pathophysiological mechanisms of visfatin.
Recently, a goal of physicians has been to use clinical markers to identify patients at risk for ACS. Wang et al. [46] suggested that visfatin may be an independent risk factor of coronary heart disease and that increased levels of visfatin may be involved in the occurrence and development of coronary heart disease. The Jupiter trial demonstrated that a daily dose of 20 mg of rosuvastatin significantly lowered cardiovascular mortality in lowand/or intermediate-risk patients with LDL-C levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels over 2 mg/L. However, no single biomarker can sufficiently predict the risk for coronary artery disease [47] . For example, multimarker risk assessment tools are better than LDL alone [48] . We think that, since it increases in the early period of ACS, visfatin may be a helpful parameter added to a multimarker panel for initial protection of low and moderate risk patients.
Visfatin was first investigated in our study as a biomarker for ACS monitoring. Classic cardiac markers, such as troponins and CK-MB, have already been used in the diagnosis and monitoring of patients with ACS. Cardiac troponins have shown to be advantageous as a powerful risk assessment tool, having greater specificity and sensitivity, and making detection of recent MI possible up to 2 weeks after onset, and being useful in the selection of therapy. However, the low sensitivity in early period of MI and requirements of repeated measurements 8 to 12 hours after onset, when results are negative, are disadvantages of the troponins [49] . In our study, increased visfatin levels in the early period of ACS decreased after first 6 hours. After the first 12 hour period, no significant difference in visfatin level was found between T1 and T2 measurements.
The recent development of a high-sensitive cardiac troponin T assay permits detection of very low levels of troponin T. Using the high-sensitive cardiac troponin T assay improves the overall diagnostic effectivity in patients with uncertain acute MI, while a negative result also has a high negative predictive value. In emergency patients with acute MI symptoms, high-sensitive cardiac troponin T significantly improves the early diagnosis of acute MI in comparison with the standard troponin T assay [50] .
Conclusion
In conclusion, visfatin demonstrated a significant positive correlation with troponin-T. Increased visfatin levels decreased significantly after the first 6 hours. Therefore, visfatin cannot be a good biomarker in the monitoring of ACS patients. Although visfatin revealed no superiority to troponins in the early diagnosis and monitoring of ACS, since its increase is correlated with troponin T, it could be an addition to a multimarker panel used in the first 6 hours. In order to understand the role of visfatin in the early period of ACS, the pathophysiological mechanisms have to be further clarified.
